Nautilus Capital
01Strategies
02Holdings
03Insights
04Team

Nautilus Capital

ir@nautiluscapital.com

A Global Perspective

Nautilus Capital

399 Park Avenue, New York, NY 10022

+1 (212) 555-0184

ir@nautiluscapital.com

HomeHoldingsStrategies
InsightsTeam
© 2026 Nautilus Capital, All Rights Reserved.
Abstract Background

Newsroom
&Insights

The nexus of institutional macro strategy and cross-asset execution.

High-conviction analysis for the sophisticated allocator.

Why BlackRock’s Ethereum ETF Could Be the Decade’s Biggest Trade
Stocks• 6 min

Why BlackRock’s Ethereum ETF Could Be the Decade’s Biggest Trade

BlackRock’s ETHA has surpasssed $10 billion in AUM, fueled by institutional demand and the GENIUS Act. With rising global liquidity and a potential move to $16,000, we analyze why Ethereum is the decade's biggest trade.

Read
FUNDSTRAT GRANNY SHOTS US LARGE CAP: High-Conviction Thematic Investing
Stocks• 4 min

FUNDSTRAT GRANNY SHOTS US LARGE CAP: High-Conviction Thematic Investing

Fundstrat’s GRNY ETF combines a top-down fundamental research framework with a quantitative, bottom-up stock selection process. We dive into the seven core themes driving its massive outperformance against the S&P 500.

Read
Peloton: The Netflix of Fitness or a Subscription Gamble?
Stocks• 8 min

Peloton: The Netflix of Fitness or a Subscription Gamble?

Peloton has transformed from a volatile, hardware-driven business into a durable, profitable subscription model. We deconstruct the $55 habit with software-like margins.

Read
Viking Therapeutics: Undervalued Leader in the Next Obesity Drug Revolution
Stocks• April 16, 2026

Viking Therapeutics: Undervalued Leader in the Next Obesity Drug Revolution

Viking Therapeutics is emerging as a top contender in the trillion-dollar obesity market. With superior Phase 2 data for its oral pill VK2735 and strong buyout potential, we explore why this biotech is deeply undervalued.

Read
All8
Stocks4
Macro2
Crypto1
Newsroom1